JP2013543869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543869A5 JP2013543869A5 JP2013538963A JP2013538963A JP2013543869A5 JP 2013543869 A5 JP2013543869 A5 JP 2013543869A5 JP 2013538963 A JP2013538963 A JP 2013538963A JP 2013538963 A JP2013538963 A JP 2013538963A JP 2013543869 A5 JP2013543869 A5 JP 2013543869A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 238000002648 combination therapy Methods 0.000 claims 8
- 230000000259 anti-tumor effect Effects 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41377110P | 2010-11-15 | 2010-11-15 | |
| US61/413,771 | 2010-11-15 | ||
| PCT/US2011/060520 WO2012067981A1 (en) | 2010-11-15 | 2011-11-14 | Combination therapy for b cell lymphomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013543869A JP2013543869A (ja) | 2013-12-09 |
| JP2013543869A5 true JP2013543869A5 (enExample) | 2015-01-15 |
Family
ID=46084355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538963A Pending JP2013543869A (ja) | 2010-11-15 | 2011-11-14 | Ｂ細胞リンパ腫のための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130330328A1 (enExample) |
| EP (1) | EP2640416A4 (enExample) |
| JP (1) | JP2013543869A (enExample) |
| KR (1) | KR20130130726A (enExample) |
| CN (1) | CN103228291A (enExample) |
| AU (1) | AU2011329161A1 (enExample) |
| CA (1) | CA2817842A1 (enExample) |
| MX (1) | MX2013005270A (enExample) |
| RU (1) | RU2013127115A (enExample) |
| SG (1) | SG190254A1 (enExample) |
| WO (1) | WO2012067981A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2878156T3 (es) * | 2016-05-30 | 2021-11-18 | Morphosys Ag | Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes |
| EP3652206A1 (en) | 2017-07-10 | 2020-05-20 | International-Drug-Development-Biotech | Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006089133A2 (en) * | 2005-02-15 | 2006-08-24 | Duke University | Anti-cd19 antibodies and uses in oncology |
| MX363905B (es) * | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| US8323653B2 (en) * | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
-
2011
- 2011-11-14 WO PCT/US2011/060520 patent/WO2012067981A1/en not_active Ceased
- 2011-11-14 SG SG2013036512A patent/SG190254A1/en unknown
- 2011-11-14 RU RU2013127115/15A patent/RU2013127115A/ru not_active Application Discontinuation
- 2011-11-14 EP EP11841807.8A patent/EP2640416A4/en not_active Withdrawn
- 2011-11-14 CN CN2011800548133A patent/CN103228291A/zh active Pending
- 2011-11-14 US US13/885,219 patent/US20130330328A1/en not_active Abandoned
- 2011-11-14 AU AU2011329161A patent/AU2011329161A1/en not_active Abandoned
- 2011-11-14 JP JP2013538963A patent/JP2013543869A/ja active Pending
- 2011-11-14 MX MX2013005270A patent/MX2013005270A/es unknown
- 2011-11-14 KR KR1020137012967A patent/KR20130130726A/ko not_active Withdrawn
- 2011-11-14 CA CA2817842A patent/CA2817842A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240009196A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2011528720A5 (enExample) | ||
| JP2017528462A5 (enExample) | ||
| JP2017501157A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| AU2022202800B2 (en) | Combinations and uses thereof | |
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| JP2017507954A5 (enExample) | ||
| ES2808565T3 (es) | Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib | |
| JP2015532292A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| RU2625222C2 (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом | |
| EP3532098B1 (en) | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof | |
| HK1251152A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2014525926A5 (enExample) | ||
| JP2013543869A5 (enExample) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| HK40069168A (en) | Combinations and uses thereof | |
| HK40064491A (en) | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof | |
| HK40014532B (en) | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof | |
| HK40014532A (en) | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof | |
| TW201315461A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之抗腫瘤組合 |